NEW YORK (GenomeWeb) – Vertex Pharmaceuticals this week said it has submitted a supplemental new drug application with the US Food and Drug Administration for Kalydeco (ivacaftor) as a treatment for cystic fibrosis patients 18 years and older who have the R117H mutation in the CFTR gene.

Vertex estimates there are approximately 300 CF patients who are 18 or older, who have the R117H mutation – the most common residual function mutation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.